BSE: 524731 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Jenburkt Pharmaceuticals Ltd is a good quality company.
The key valuation ratios of Jenburkt Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jenburkt Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 42.4% | 40.2% | 39.3% | 42% | 36.9% | 25.7% | 23.8% | 26.9% | 26.8% | 26.3% | - |
| Value Creation Index ⓘ | 2.0 | 1.9 | 1.8 | 2.0 | 1.6 | 0.8 | 0.7 | 0.9 | 0.9 | 0.9 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 85.2 | 93.6 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 | 148 |
| Sales YoY Gr. | - | 9.8% | 10.4% | 11% | 7% | -3.1% | -8.1% | 13.4% | 10.3% | 3.8% | - |
| Adj EPS ⓘ | 20.7 | 22.9 | 28.9 | 36.9 | 43.2 | 31.8 | 35.6 | 47.9 | 54.4 | 58.3 | 68.7 |
| YoY Gr. | - | 10.5% | 26.3% | 27.7% | 17% | -26.3% | 11.8% | 34.5% | 13.6% | 7.2% | - |
| BVPS (₹) ⓘ | 71.9 | 86.4 | 117.1 | 133.5 | 168.8 | 174.3 | 214.6 | 255.8 | 277.3 | 328.4 | 357.5 |
| Adj Net Profit ⓘ | 9.6 | 10.6 | 13.4 | 17 | 19.8 | 14.6 | 16.3 | 22 | 24 | 25.7 | 30 |
| Cash Flow from Ops. ⓘ | 8.7 | 7.8 | 10 | 16.2 | 13 | 15 | 19.5 | 9.3 | 17.1 | 8.1 | - |
| Debt/CF from Ops. ⓘ | 0.8 | 0.7 | 0.6 | 0 | 0.6 | 0.2 | 0.2 | 0.6 | 0.1 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.8% | 3% | 9.1% | 3.8% | ||||
| Adj EPS ⓘ | 12.2% | 6.2% | 17.9% | 7.2% | ||||
| BVPSⓘ | 18.4% | 14.2% | 15.3% | 18.4% | ||||
| Share Price | 12.8% | 22.2% | 27.8% | 65.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 31.7 | 28.9 | 28.4 | 29.3 | 28.6 | 18.6 | 18.3 | 20.4 | 20 | 19.3 | 20 |
| Op. Profit Mgn % ⓘ | 17.9 | 17.6 | 19.1 | 20.7 | 20.4 | 16.6 | 18.2 | 22 | 22.2 | 23.3 | 25.5 |
| Net Profit Mgn % ⓘ | 11.3 | 11.4 | 13 | 14.8 | 16.2 | 12.3 | 15 | 17.7 | 17.6 | 18.1 | 20.4 |
| Debt to Equity ⓘ | 0.2 | 0.1 | 0.1 | 0 | 0.1 | 0 | 0 | 0.1 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 73 | 71 | 65 | 69 | 84 | 101 | 129 | 177 | 185 | 156 | 120 |
| Cash Conv. Cycle ⓘ | 34 | 38 | 37 | 39 | 56 | 71 | 62 | 46 | 41 | 45 | 101 |
Return on Equity has increased versus last 3 years average to 20.00%
Net Profit is growing at healthy rate in last 3 years 17.87%
Sales growth has been subdued in last 3 years 9.11%
Sales growth is not so good in last 4 quarters at 8.16%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 68.7 | - |
| TTM Sales (₹ Cr.) | 148 | - |
| BVPS (₹.) ⓘ | 357.5 | - |
| Reserves (₹ Cr.) ⓘ | 153 | - |
| P/BV ⓘ | 3.35 | - |
| PE ⓘ | 17.45 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 643.20 / 1375.00 |
| All Time Low / High (₹) | 1.80 / 1375.00 |
| Market Cap (₹ Cr.) | 529 |
| Equity (₹ Cr.) | 4.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 85 | 94 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 |
| Operating Expenses ⓘ | 70 | 77 | 84 | 91 | 98 | 99 | 89 | 97 | 106 | 109 |
| Manufacturing Costs | 5 | 5 | 4 | 5 | 5 | 5 | 4 | 6 | 7 | 7 |
| Material Costs | 23 | 25 | 28 | 31 | 33 | 30 | 28 | 27 | 29 | 27 |
| Employee Cost | 19 | 21 | 25 | 28 | 31 | 37 | 32 | 36 | 39 | 42 |
| Other Costs ⓘ | 23 | 25 | 26 | 27 | 28 | 28 | 25 | 26 | 32 | 33 |
| Operating Profit ⓘ | 15 | 16 | 20 | 24 | 25 | 20 | 20 | 27 | 30 | 33 |
| Operating Profit Margin (%) | 17.9% | 17.6% | 19.1% | 20.7% | 20.3% | 16.6% | 18.2% | 22.0% | 22.2% | 23.3% |
| Other Income ⓘ | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 14 | 17 | 20 | 25 | 27 | 21 | 22 | 30 | 33 | 35 |
| Tax ⓘ | 5 | 6 | 7 | 8 | 7 | 6 | 5 | 8 | 8 | 9 |
| Profit After Tax | 10 | 11 | 14 | 17 | 20 | 15 | 17 | 22 | 25 | 26 |
| PAT Margin (%) | 11.3% | 11.5% | 13.1% | 15.0% | 16.1% | 12.5% | 15.1% | 18.0% | 18.0% | 18.3% |
| Adjusted EPS (₹) | 20.8 | 23.2 | 29.1 | 37.5 | 43.1 | 32.4 | 36.0 | 48.6 | 55.8 | 58.9 |
| Dividend Payout Ratio (%) | 30% | 31% | 28% | 24% | 24% | 25% | 28% | 25% | 26% | 26% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 33 | 40 | 54 | 61 | 77 | 80 | 98 | 117 | 122 | 145 |
| Share Capital ⓘ | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Reserves ⓘ | 29 | 36 | 50 | 57 | 73 | 75 | 94 | 113 | 118 | 141 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 7 | 5 | 6 | 0 | 7 | 3 | 4 | 6 | 2 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 7 | 5 | 6 | 0 | 7 | 3 | 4 | 6 | 2 | 0 |
| Trade Payables | 4 | 3 | 6 | 4 | 7 | 5 | 5 | 7 | 6 | 6 |
| Others Liabilities ⓘ | 17 | 9 | 10 | 12 | 11 | 16 | 14 | 12 | 10 | 13 |
| Total Liabilities ⓘ | 61 | 58 | 76 | 78 | 103 | 104 | 120 | 143 | 141 | 164 |
Fixed Assets | ||||||||||
| Gross Block | 23 | 26 | 25 | 26 | 27 | 31 | 32 | 33 | 34 | 34 |
| Accumulated Depreciation | 12 | 13 | 15 | 16 | 17 | 20 | 21 | 22 | 24 | 23 |
| Net Fixed Assetsⓘ | 12 | 12 | 11 | 10 | 10 | 12 | 11 | 11 | 10 | 10 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Investmentsⓘ | 0 | 1 | 2 | 5 | 5 | 4 | 7 | 8 | 11 | 17 |
| Inventories | 8 | 8 | 11 | 7 | 10 | 11 | 8 | 10 | 8 | 9 |
| Trade Receivables | 7 | 6 | 9 | 13 | 23 | 18 | 14 | 15 | 17 | 19 |
Cash Equivalents  ⓘ
| 28 | 30 | 42 | 41 | 52 | 58 | 57 | 49 | 54 | 79 |
| Others Assetsⓘ | 6 | 2 | 2 | 2 | 2 | 2 | 25 | 49 | 40 | 29 |
| Total Assets ⓘ | 61 | 58 | 76 | 78 | 103 | 104 | 120 | 143 | 141 | 164 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 9 | 8 | 10 | 16 | 13 | 15 | 19 | 9 | 17 | 8 |
| PBT ⓘ | 14 | 17 | 20 | 25 | 27 | 21 | 22 | 30 | 33 | 35 |
| Adjustment ⓘ | 1 | -1 | -1 | -2 | -2 | -1 | -2 | -2 | -2 | 0 |
| Changes in Working Capital ⓘ | -2 | -3 | -3 | 1 | -5 | 1 | 5 | -11 | -6 | -18 |
| Tax Paid ⓘ | -5 | -6 | -7 | -8 | -7 | -5 | -6 | -8 | -8 | -8 |
| Cash Flow From Investing Activity ⓘ | 1 | 0 | -10 | 1 | -11 | -3 | -19 | -1 | 3 | -1 |
| Capex | -1 | -2 | 0 | 0 | -2 | -4 | -1 | -3 | -2 | -3 |
| Net Investments | 0 | 0 | 32 | -2 | -11 | -2 | -21 | -4 | 3 | -4 |
| Others ⓘ | 2 | 3 | -41 | 3 | 3 | 2 | 4 | 5 | 2 | 6 |
| Cash Flow From Financing Activityⓘ | 1 | -5 | 1 | -18 | -2 | -11 | -1 | -6 | -21 | -7 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -1 | 0 |
| Dividend Paid ⓘ | -3 | -3 | 0 | -7 | -1 | -9 | 0 | -5 | -5 | -6 |
| Others ⓘ | 4 | -2 | 1 | -11 | -1 | -2 | -1 | -1 | -15 | -1 |
| Net Cash Flow ⓘ | 11 | 2 | 1 | -1 | 0 | 1 | 0 | 3 | -1 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 31.77 | 29.28 | 28.55 | 29.75 | 28.54 | 18.89 | 18.49 | 20.66 | 20.53 | 19.43 |
| ROCE (%) | 42.35 | 40.17 | 39.26 | 41.99 | 36.9 | 25.73 | 23.83 | 26.89 | 26.8 | 26.28 |
| Asset Turnover Ratio | 1.65 | 1.6 | 1.56 | 1.49 | 1.36 | 1.15 | 0.97 | 0.94 | 0.96 | 0.93 |
| PAT to CFO Conversion(x) | 0.9 | 0.73 | 0.71 | 0.94 | 0.65 | 1 | 1.12 | 0.41 | 0.68 | 0.31 | Working Capital Days |
| Receivable Days | 27 | 25 | 26 | 34 | 53 | 63 | 53 | 43 | 43 | 47 |
| Inventory Days | 30 | 30 | 33 | 28 | 25 | 32 | 31 | 26 | 24 | 22 |
| Payable Days | 62 | 51 | 61 | 59 | 59 | 71 | 65 | 78 | 84 | 85 |
Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta
Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations
The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.
The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.
Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.
Product range of the company includes:
Consumer Division:
Pharmaceutical Division:
Awards
2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
